During breast-conserving surgeries, axillary lymph nodes draining from the primary tumor site are removed for disease staging. Although a high number of lymph nodes are often resected during sentinel and lymph-node dissections, only a relatively small percentage of nodes are found to be metastatic, a fact that must be weighed against potential complications such as lymphedema. Without a real-time in vivo or in situ intraoperative imaging tool to provide a microscopic assessment of the nodes, postoperative paraffin section histopathological analysis currently remains the gold standard in assessing the status of lymph nodes. Optical coherence tomography (OCT), a high-resolution real-time microscopic optical-imaging technique previously used to image breast cancer tumor margins intraoperatively in humans and lymph-node microarchitecture in a rat animal model, is being presented for the intraoperative ex vivo imaging and assessment of axillary lymph nodes. OCT provides real-time microscopic images up to 2 mm beneath the tissue surface in axillary lymph nodes. Normal (13), reactive (1), and metastatic (3) lymph nodes from 17 human patients with breast cancer were imaged intraoperatively with OCT. These preliminary clinical studies have identified scattering changes in the cortex, relative to the capsule, which can be used to differentiate normal from reactive and metastatic nodes. These optical scattering changes are correlated with inflammatory and immunological changes observed in the follicles and germinal centers. These results suggest that intraoperative OCT has the potential to assess the real-time node status in situ, without having to physically resect and histologically process specimens to visualize microscopic features.
Breast CancerBreast cancer continues to affect a significant proportion of women, as 192,370 new cases of invasive breast cancer and 62,280 cases of ductal carcinoma in situ (DCIS) are expected in the United States during 2009, making it the most widely diagnosed cancer (26% of new cases) in women [1]. The number of deaths attributed to breast cancer (40,610 expected in 2009-second only to lung cancer) has started to decrease over the last few years, largely attributed to the effectiveness of breast-cancer screening [1]. These developments have led to the increased detection of breast-cancer lesions at earlier stages, resulting in smaller breast lesions and a decreased likelihood of lymph-node involvement and cancer metastasis. The management and treatment of breast cancer has continued to improve, as evidenced by the gradual increases in the five-year survival rates for all stages of breast cancer [2]. Currently, patients electing to undergo lumpectomies or mastectomies will typically have a sentinel lymph-node dissection (SLND), which may be accompanied by the removal of additional axillary lymph nodes via axillary lymph-node dissection (ALND) to help stage . Staging is based on the size of the primary tumor, the involvement of lymph nodes, and the metastatic spread to secondary sites.
Ma...